H.C. Wainwright Raises Rapport Therapeutics (NASDAQ: RAPP) Price Target to $66 Following Positive RAP-219 Phase 2 Data
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAvedro Inc
-
Registration countryUSA
-
IndustryMiscellaneous Healthcare: Products and Services
-
М/S&P/F
*** /*** /***










